Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Meningococcal Meningitis Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors

NCT04224311
View directory record Official record
Conditions
Preventive Immunization; Meningitis
Interventions
Menactra
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

NCT02500511
View directory record Official record
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
NmVac4-A/C/Y/W-135-DT™
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

NCT00772070
View directory record Official record
Conditions
Meningitis, Meningococcemia, Neisseria Meningitidis
Interventions
A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
3 Years to 5 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
8
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Woburn, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

NCT00700713
View directory record Official record
Conditions
Meningitis, Meningococcemia
Interventions
Meningococcal polysaccharide diphtheria toxoid conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
3 Years to 6 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
13
States / cities
Marietta, Georgia • Woodstock, Georgia • Bardstown, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

NCT02199691
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
1,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

NCT01482052
View directory record Official record
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
meningococcal meningitis conjugate vaccine, quadrivalent
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

NCT00616421
View directory record Official record
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM, Licensed meningococcal ACWY vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Years to 10 Years
Enrollment
2,907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
52
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

NCT00459316
View directory record Official record
Conditions
HIV Infections, Meningitis
Interventions
Quadrivalent meningococcal conjugate vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
35
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

NCT00862277
View directory record Official record
Conditions
Meningococcal Infections, Meningitis
Interventions
Menactra®, Menomune®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
14 Years to 27 Years
Enrollment
763 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
20
States / cities
Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

NCT00728260
View directory record Official record
Conditions
Meningitis, Meningococcal Disease
Interventions
None administered in this study
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
1,421 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

NCT00483574
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

NCT01461993
View directory record Official record
Conditions
Vaccines, Meningococcal Vaccines
Interventions
rLP2086 and Gardasil, rLP2086, Gardasil
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 17 Years
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
87
States / cities
Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

NCT01732627
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections, Invasive Meningococcal Disease
Interventions
Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
56 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Scottsdale, Arizona • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 6 Years
Enrollment
387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
14
States / cities
Benton, Arkansas • Little Rock, Arkansas • Antioch, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

NCT01768117
View directory record Official record
Conditions
Meningitis, Meningococcal, Serogroup B
Interventions
rLP2086
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High and Low Resource Interventions to Promote HPV Vaccines

NCT03824093
View directory record Official record
Conditions
Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication, Satisfaction
Interventions
AFIX Only, AFIX+ Provider Communication Training
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

NCT00355121
View directory record Official record
Conditions
Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 7 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
26
States / cities
Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

NCT01239043
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi
Industry
Eligibility
56 Years and older
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2012 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

NCT00626327
View directory record Official record
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
7 Months to 1 Year
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
90
States / cities
Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

NCT01272180
View directory record Official record
Conditions
Invasive Meningococcal Disease
Interventions
Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

NCT00297817
View directory record Official record
Conditions
Meningococcal Disease
Interventions
serogroup B meningococcal vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 18 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
8
States / cities
Encinitas, California • Atlanta, Georgia • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

NCT02986854
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 55 Years
Enrollment
704 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

NCT03077438
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Years to 9 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
35
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jul 20, 2026, 6:42 PM EDT